Journal of Clinical Epidemiology
Volume 50, Issue 7 , Pages 813-822 , July 1997

Cost-Benefit Analyses in the Health-Care Literature: Don't Judge a Study by Its Label

  • Kelly B Zarnke

      Affiliations

    • Departments of Medicine and Clinical Pharmacology, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada N6A 5A5
    • Centre for Evaluation of Medicines, St. Joseph's Hospital, Hamilton, Ontario, Canada L8N 4A6
    • Corresponding Author InformationDr. Kelly B. Zarnke, M.D., London Health Sciences Centre, University Campus, Rm 5OF17, 339 Windermere Road, London, Ontario, Canada N6A 5A5
    • ,
  • Mitchell A.H Levine

      Affiliations

    • Centre for Evaluation of Medicines, St. Joseph's Hospital, Hamilton, Ontario, Canada L8N 4A6
    • Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
    • ,
  • Bernie J O'Brien

      Affiliations

    • Centre for Evaluation of Medicines, St. Joseph's Hospital, Hamilton, Ontario, Canada L8N 4A6
    • Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada L8N 3Z5

,Accepted 24 March 1997.

References 

  1. Warner KE, Hutton RC. Cost-benefit and cost-effectiveness analysis in health care. Growth and composition of the literature. Med Care. 1980;17:1069–1084
  2. Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA (An update of the growth and composition of the literature). Med Care. 1993;31:JS1–JS11
  3. Drummond MF. Survey of cost-effectiveness and cost-benefit analyses in industrialized countries. World Health Stat Quarterly. 1985;38:383–401
  4. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term “cost effective” in medicine. N Engl J Med. 1986;314:253–255
  5. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Int Med. 1992;116:238–244
  6. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1987;
  7. Ontario Ministry of Health . Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Queen's Printer for Ontario; 1994;
  8. Commonwealth Department of Human Services and Health . Guidelines for the Pharmaceutical Industry on the Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Publishing Service; 1995;
  9. Canadian Coordinating Office for Health Technology Assessment . Guidelines for the Economic Evaluation of Pharmaceuticals (Canada). Ottawa: CCOHTA Press; 1994;
  10. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716–721
  11. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473–481
  12. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables (More harm than good?). Social Sci Med. 1993;37:33–40
  13. Mishan EJ. Evaluation of life and limb (A theoretical approach). J Political Economy. 1971;79:687–705
  14. O'Brien BJ, Gafni A. When do the dollars make sense? Towards a conceptual framework for contingent valuation studies in health care. Med Decision Making. 1996;16:288–299
  15. Neumann PJ, Johannesson M. The willingness to pay for in vitro fertilization (A pilot study using contingent valuation). Med Care. 1994;32:686–699
  16. O'Brien BJ, Novosel S, Torrance G, Steiner D. Assessing the economic value of a new antidepressant. PharmacoEconomics. 1995;8:34–45
  17. Johannesson M, Jonsson B. Economic evaluation in health care (Is there a role for cost-benefit analyses?). Health Policy. 1991;17:1–23
  18. Gafni A. Willingness-to-pay as a measure of benefits (Relevant questions in the context of public decision making about health care programs). Med Care. 1991;29:1246–1252
  19. Robinson R. Cost-benefit analysis. Br Med J. 1993;307:924–926
  20. Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics. Cincinnati: Harvey Whitney Books Co; 1991;
  21. Sugden R, Williams A. The principles of practical cost-benefit analysis. Oxford: Oxford University Press; 1978;
  22. CDC/WHO . Epi Info. Atlanta: CDC; 1994;Version 6.0
  23. Sexner S, Adams VG, Hundahl LS, Lau S, Adessa CJ, Hopkins D. A smoking cessation pilot program. Hawaii Med J. 1993;52:266–272
  24. Starr RL, Sherman ME. The value of multiple preparations in the diagnosis of malignant pleural effusions. Acta Cytologica. 1991;35:533–537
  25. Shireman TI, Hilsenrath PE, Strauss RG, Widness JA, Mutnick AH. Recombinant human erythropoietin vs transfusiona in the treatment of anemia of prematurity. Arch Ped Adolescent Med. 1994;148:582–588
  26. Yates BT, Yokley JM, Thomas JV. Cost-benefit analysis of six alternative payment incentives for child therapists. J Consulting Clin Psych. 1994;62:627–635
  27. Hueston WJ, Mainous AG, Farrell JB. A cost-benefit analysis of smoking cessation programs during the first trimester of pregnancy for the prevention of low birthweight. J Family Practice. 1994;39:353–357
  28. Davids JR, Benson LJ, Mubarak SJ, McNeil N. Ultrasonography and developmental dysplasia of the hip (A cost-benefit analysis of three delivery systems). J Ped Orthopedics. 1995;15:325–329
  29. Jonsson B, Horisberger B, Bruguera M, Matter L. Cost-benefit analysis of hepatitis B vaccination. Int J Technology Assessment Health Care. 1991;7(3):379–402
  30. Ponto JM, Berg W. Social work services in the emergency department (A cost-benefit analysis of the extended coverage program). Health and Social Work. 1992;17:66–73
  31. Peterson CM, Poulson AM, Hatasaka HH, Carrell DT, Jones KP, Urry RL. Ovulation induction with gonadotropins and intrauterine insemination compared with in vitro fertilization and no therapy (A prospective, nonrandomized, cohort study and meta-analysis). Fertility and Sterility. 1994;62:535–544
  32. Stimson L. Caseload midwifery—a cost-benefit analysis. Modern Midwife. 1995;5:4–6
  33. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii Pneumonia. J Am Med Assoc. 1991;266:820–824
  34. Rouse DJ, Andrews WW, Goldenberg RL, Owen J. Screening and treatment of asymptomatic bacteruria of pregnancy to prevent pyelonephritis (A cost-effectiveness and cost-benefit analysis). Obstetrics and Gynecology. 1995;86:119–123
  35. Phillips KA, Lowe RA, Kahn JG, Lurie P, Avins AL, Ciccarone D. The cost-effectiveness of HIV testing of physicians and dentists in the United States. J Am Med Assoc. 1994;271:851–858
  36. Arrigoni A, Pennazio M, Rossini FP. Rectosigmoid polyps as markers of proximal colonic neoplasms (A cost-benefit analysis of different diagnostic protocols). Anticancer Res. 1995;15:563–568
  37. Petersson LG, Westberg I. Intensive fluoride varnish program in Swedish adolescents (economic assessment of a 7-year follow-up program study on proximal caries incidence). Caries Res. 1994;28:59–63
  38. Jones TF, Eaton CB. Cost-benefit analysis of walking to prevent coronary heart disease. Arch Family Med. 1994;3:703–710
  39. Bel S, Bauer BL. Dorsal column stimulation (DCS) (Cost to benefit ratio). Acta Neurochirurgica. 1991;52(Suppl.):121–123
  40. Hassell JT, Games AD, Shaffer B, Harkins LE. Nutrition support team management of the enterally fed patients in a community hospital is cost-beneficial. J Am Dietetic Assoc. 1994;94:993–998
  41. Holt AW, Bersten AD, Fuller S, Piper RK, Worthley LIG, Vedig AE. Intensive care costing methodology (Cost-benefit analysis of mask continous positive airway pressure for severe cardiogenic pulmonary edema). Anaesthesia and Intensive Care. 1994;22:170–174
  42. Laakso M, Lahtinen R, Virkkunen P, Elomma I. Subgroup and cost-benefit analysis of the Finnish multiventre trial of clodronate in multiple myeloma. Br J Haematol. 1994;87:725–729
  43. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP. Pharmaco-economic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hospital Pharm. 1994;51:1555–1563
  44. Johannesson M, Aberg H, Agreus L, Borgquist L, Jonsson B. Cost-benefit analysis of non-pharmacological treatment of hypertension. J Int Med. 1991;230:307–312
  45. Hauch O, Khattar SC, Jorgensen LN. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery. Sem Thrombosis Hemostasis. 1991;17(Suppl. 3):280–283
  46. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med. 1995;98:464–468
  47. Ortmeier BG, Sauer KA, Langley PC, Bealmear BK. A cost-benefit analysis of four hormonal contraceptive methods. Clin Therapeutics. 1994;16:707–713
  48. Pinilla J, Shafran S, Conly J. A utilization and cost-benefit analysis of an aminoglycoside kinetics monitoring service. Clin Invest Med. 1992;15:8–17
  49. Pennings JL, Bachulis BL, Simons CT, Slazinski T. Survival after severe brain injury in the aged. Arch Surgery. 1993;128:787–794
  50. Alvarez C, Livingston EH, Ashley SW, Schwarz M, Reber HA. Cost-benefit analysis of the work-up for pancreatic cancer. Am J Surgery. 1993;165:53–60
  51. Goldstein H. Studies of various aspects of Down syndrome in Denmark, and their use as an epidemiological basis for cost-benefit analysis of genetic amniocentesis. Danish Med Bull. 1992;39:489–508
  52. Massad LS, Lonky NM, Mutch DG, Mann WJ, Blanco JS, Vasilev SA, et al.  Use of speculoscopy in the evaluation of women with atypical Papanicolaou smears (Improved cost effectiveness by selective colposcopy). J Reproductive Med. 1993;38:163–169
  53. Maruri F, Azziz R. Laparscopic surgery for ectopic pregnancies (Technologicy assessment and public health implications). Fertility and Sterility. 1993;59:487–498
  54. Windsor RA, Lowe JB, Perkins LL, Smith-Yoder D, Artz L, Crawford M, et al.  Health education for pregnant smokers (Its behavioral impact and cost benefit). Am J Public Health. 1993;83:201–206
  55. Schumacher RE, Roloff DW, Chapman R, Snedecor S, Bartlett RH. Extracorporeal membrane oxygenation in term newborns (A prospective cost-benefit analysis). ASAIO J. 1993;39:873–879
  56. Buescher PA, Larson LC, Nelson MD, Lenihan AJ. Prenatal WIC participation can reduce low birth weight and newborn medical costs (A cost-benefit analysis of WIC participation in North Carolina). J Am Dietetic Assoc. 1993;93:163–166
  57. Levine OS, Ortiz E, Contreras R, Lagos R, Vial P, Misraji A, et al.  Cost-benefit analysis for the use of Haemophilus influenzae Type b conjugate vaccine in Santiago, Chile. Am J Epidemiol. 1993;137:1221–1228
  58. Seror V, Muller F, Moatti JP, Le Gales C, Boue A. Economic assessment of maternal serum screening for Down's Syndrome using human chorionic gonadotropin. Prenatal Diagnosis. 1993;13:281–292
  59. Elixhauser A, Weschler JM, Kitzmiller JL, Marks JS, Bennert HW, Coustan DR, et al.  Cost-benefit analysis of preconception care for women with established diabetes mellitus. Diabetes Care. 1993;18:1146–1157
  60. Kelley JE, Burrus RG, Burns RP, Graham LD, Chandler KE. Safety, efficacy, cost, and morbidity of laparoscopic versus open cholecystectomy. Am Surgeon. 1993;59:23–27
  61. Ridley S, Biggam M, Stone P. A cost-benefit analysis of intensive therapy. Anaesthesia. 1993;48:14–19
  62. Humphreys JT, Henneberry JF, Rickard RS, Beebe JL. Cost-benefit analysis of selective screening criteria for Chlamydia trachomatis infection in women attending Colorado family planning clinics. Sexually Transmitted Diseases. 1992;19:47–53
  63. Schiotz HA, Csango PA. Test-of-cure for asymptomatic genital chlamydial infections in women (A cost-benefit analysis). Sexually Transmitted Diseases. 1992;19:133–136
  64. Warner S, Welch R. The cost-benefits of a nursing demonstration project, Part III. Arch Psych Nursing. 1993;7:68–73
  65. Ginsberg GM, Viskoper JR, Fuchs Z, Drexler I, Lubin F, Berlin S, et al.  Partial cost-benefit analysis of two different modes of nonpharmacological control of hypertension in the community. J Human Hypertension. 1993;7:593–597
  66. Zwerling C, Ryan J, Ovar J. Costs and benefits of preemployment drug screening. J Am Med Assoc. 1992;267:91–93
  67. Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal Group B streptococcal infection (A population-based economic analysis). J Am Med Assoc. 1993;270:1442–1448
  68. Combs CA, Murphy EL, Laros RK. Cost-benefit analysis of autologous blood transfusion in obstetrics. Obstetrics and Gynecology. 1992;80:621–625
  69. Vrtis MC. Cost/benefit analysis of cardiopulmonary resuscitation (A comprehensive study—Part II). Nursing Management. 1992;23:44–51
  70. Buch JP, Zorn BH, Taylor RJ. Cost-benefit analysis of pharmacological erection program (PEP) versus penile prosthesis. Urology. 1991;37:116–118
  71. Droste S, Keil K. Expectant management of placenta previa (Cost-benefit analysis of outpatient treatment). Am J Obstetrics Gynecology. 1994;170:1254–1257
  72. Parker MJ, Myles JW, Anand JK, Drewett R. Cost-benefit analysis of hip fracture treatment. J Bone Joint Surg. 1992;74B:261–264
  73. Esuvaranathan K, Tan EC, Tan PK, Tung KH. Does transurethral laser ureterolithotripsy justify its costs?. J Urology. 1992;148:1091–1094
  74. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?. Br Med J. 1993;306:1722–1725
  75. Carrasco G, Molina R, Costa J, Soler JM, Cabre L. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. Chest. 1993;103:557–564
  76. Schofield CJ, Dias JCP. A cost-benefit analysis of Chagas disease control. Memorias do Instituto Oswaldo Cruz. 1991;86:285–295
  77. Mohle-Boetani JC, Miller B, Halpern M, Trivedi A, Lessler J, Solomon SL, et al.  School-based screening for tuberculous infection. J Am Med Assoc. 1995;274:613–619
  78. Vilos GA, Alshimmiri MM. Cost-benefit analysis of laparscopic versus laparotomy salpingo-oophorectomy for benign tubo-ovarian disease. J Am Assoc Gynecologic Laparoscopists. 1995;2:299–303
  79. Turner DM, Warson JS, Wirt TC, Scalley RD, Cochran RS, Miller KJ. The use of ketorolac in lumbar spine surgery (A cost-benefit analysis). J Spinal Disorders. 1995;8:206–212
  80. McCallum JE, Turbeville D. Cost and outcome in a series of shunted premature infants with intraventricular hemorrhage. Pediatric Neurosurgery. 1994;20:63–67
  81. Faronato P, de Bigontina G. A cost/benefit analysis of two mass screening strategies for albuminuria in diabetic patients. Diabetes, Nutrition and Metabolism. 1994;7:325–329
  82. Benson MJ, Cahalan MK. Cost-benefit analysis of transesophageal echocardiography in cardiac surgery. Echocardiography. 1995;12:171–183
  83. Glazebrook GA. Radiation therapy (A long term cost benefit analysis in a North American region). Clin Oncol. 1992;4:302–305
  84. Baniel J, Roth BJ, Foster RS, Donohue JP. Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors. Cancer. 1995;75:2897–2903
  85. Linton SJ, Bradley LA. An 18-month follow-up of a secondary prevention program for back pain (Help and hindrance factors related to outcome maintenance). Clin J Pain. 1992;8:227–236
  86. Granberg M, Wikland M, Nilsson L, Hamberger L. Couples' willingness to pay for IVF/ET. Acta Obstetricia et Gynecologica Scandinavica. 1995;74:199–202
  87. Prince JM, Manley MS, Whiteneck GG. Self-management versus agency-provided personal assistance care for individuals with high level tetraplegia. Arch Physical Med Rehab. 1995;76:919–923
  88. Ginsberg GM, Silverberg DS. A cost-benefit analysis of legislation for bicycle safety helmets in Israel. Am J Public Health. 1994;84:653–656
  89. Romano PS, Waitzman NJ, Scheffler RM, Pi RD. Folic acid fortification of grain (An economic analysis). Am J Public Health. 1995;85:667–676
  90. Ginsberg GM, Berger S, Shouval D. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity. Bull World Health Organization. 1992;70:757–767
  91. Hisashige A. Health economic analysis of the neonatal screening program in Japan. Int J Tech Assess Health Care. 1994;10:382–391
  92. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of childbearing age for human immunodeficiency virus. Arch Int Med. 1992;152:2229–2237
  93. Fric P, Zavoral M, Dvorakova H, Zoubek V, Roth Z. An adapted program of colorectal cancer screening—7 years experience and cost-benefit analysis. Hepato-Gastroenterology. 1994;41:413–416
  94. Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health. 1995;85:843–845
  95. McKay NL, Philips KM. An economic evaluation of mandatory premarital testing for HIV. Inquiry. 1991;28:236–248
  96. Rutz W, Carlsson P, von Knorring L, Walinder J. Cost-benefit analysis of an educational program for general practioners by the Swedish Committee for the Prevention and Treatment of Depression. Acta Psychiatrica Scandinavica. 1992;85:457–464
  97. Starostina EG, Antsiferov M, Galstyan GR, Trautner C, Jorgens V, Bott U, et al.  Effectiveness and cost-benefit analysis of independent treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow—blood glucose versus urine glucose self monitoring. Diabetologia. 1994;37:170–176
  98. Taitel MS, Kotses H, Bernstein IL, Bernstein DI, Creer TL. A self-management program for adult asthma. Part II (Cost-benefit analysis). J Allergy Clin Immunol. 1995;95:672–676
  99. Demicheli V, Jefferson TO. Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy. J Public Health Med. 1992;14:367–375
  100. Ginsberg GM, Blau H, Kerem E, Springer C. Cost-benefit analysis of a national screening program for cystic fibrosis in an Israel population. Health Economics. 1994;3:5–23
  101. Trollfors B. Cost-benefit analysis of general vaccination against Haemophilus influenza type b in Sweden. Scand J Infect Dis. 1994;26:611–614
  102. Levy DT, Miller TR. A cost-benefit analysis of enforced efforts to reduce serving intoxicated patrons. J Studies Alcohol. 1995;56:240–247
  103. Van Den Broek JG, Weatherburn H. Re-evaluation of a radiation protection cost-benefit analysis study in brachytherapy. Br J Radiol. 1994;67:59–62
  104. Colby SB, Wochos JF. An assessment of overbadging at a large clinic. Health Physics. 1993;64:538–539
  105. Shi L. A cost-benefit analysis of a California county's back injury prevention program. Public Health Reports. 1993;108:204–211
  106. Ginsberg GM, Kassis I, Dagan R. Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel. J Epidemiol Comm Health. 1993;47:485–490
  107. Reed SK, Hennessy KD, Mitchell OS, Babigian HM. A mental health capitation program (II. Cost-benefit analysis). Hospital Comm Psych. 1994;45:1097–1103
  108. Jefferson TO, Behrens RH, Demicheli V. Should British soldiers be vaccinated against hepatitis A? An economic analysis. Vaccine. 1994;12:1379–1383
  109. Ginsberg GM, Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Comm Health. 1992;46:587–594
  110. Holtgrave DR, Valdiserri RO, Gerber AR, Hinman AR. Human immunodeficiency virus counseling, testing, referal, and partner notification services (A cost-benefit analysis). Arch Int Med. 1993;153:1225–1230
  111. Musgrove P. Cost-benefit analysis of a regional system for vaccination against pneumonia, meningitis type B, and typhoid fever. Bull Pan Am Health Organization. 1992;26:173–191
  112. Mauskopf JA, Bradley CJ, French MT. Benefit-cost analysis of Hepatitis B vaccine programs for occupationally exposed workers. J Occupational Med. 1991;33:691–698
  113. Le Pen C, Levy E, Ravily V, Beuzen JN, Meurgey F. The cost of treatment dropout in depression (A cost-benefit analysis of fluoxetine vs tricyclics). J Affective Disorders. 1994;31:1–18
  114. Tintara H, Leetanaporn R. Cost-benefit analysis of laparoscopic adnexectomy. Int J Gynecology Obstetrics. 1995;50:21–25
  115. Lappalainen M, Sintonen H, Koskiniemi M, Hedman K, Hiilesmaa V, Ammala P, et al.  Cost-benefit analysis of screening for Toxoplasmosis during pregnancy. Scand J Infect Dis. 1995;27:265–272
  116. Johannesson M, Fagerberg B. A health-economic comparison of diet and drug treatment in obese men with mild hypertension. J Hypertension. 1992;10:1063–1070
  117. Hussey GD, Lasser ML, Reekie WD. The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease. South African Med J. 1995;85:20–25
  118. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418–1424
  119. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med. 1977;296:732–739
  120. Johannesson M. The impact of age on the cost-effectiveness of hypertension treatment (An analysis of randomized drug trials). Medical Decision Making. 1994;14:236–244
  121. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary artery disease (Estimating the benefits of increasing HDL-C). J Am Med Assoc. 1995;273:1032–1038
  122. Mitchell RC, Carson RT. Using Surveys to Value Public Goods (The Contingent Valuation Method). Washington DC: Resources for the Future; 1989;
  123. Portney PR. The contingent valuation debate (Why economists should care). J Economic Perspectives. 1994;8:3–17
  124. Johannesson M. Economic evaluation of hypertension treatment. Int J Technol Assess Health Care. 1992;8:506–523
  125. Lindholm L, Rosen M, Hellsten G. Are people willing to pay for a community-based preventive program?. Int J Technol Assess Health Care. 1994;10:317–324
  126. Haynes R. More informative abstracts (Current status and evaluation). J Clin Epidemiol. 1993;46:595–597
  127. Wilczynski NL, Walker CJ, McKinnon KA, Haynes RB. Preliminary assessment of the effect of more informative (structured) abstracts on citation retrieval from MEDLINE. Medinfo. 1995;8:1457–1461

PII: S0895-4356(97)00064-4

Journal of Clinical Epidemiology
Volume 50, Issue 7 , Pages 813-822 , July 1997

Article Tools